Abstracts tagged "Uric Acid, Urate"

Abstract Number: 1805 • ACR Convergence 2023
Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake
Sho Fukui¹, Masato Okada², Tomohiro Shinozaki³, Takahiro Asano², Takehiro Nakai², Hiromichi Tamaki², Mitsumasa Kishimoto⁴, Hiroshi Hasegawa⁵, Takeaki Matsuda⁵, Javier Marrugo¹, Sara Tedeschi¹ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Boston, MA, ²St. Luke's International Hospital, Tokyo, Japan, ³Tokyo University of Science, Tokyo, Japan, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Kyorin University, Tokyo, Japan, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Cross-sectional epidemiologic studies support a direct relationship between alcohol intake and serum urate (SU). These observations are parts of the basis for gout recommendations…
Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
James Cheng-Chung Wei¹, Roy Fleischmann², sarah Morris³, Vijay Hingorani⁴, Elizabeth Polvent⁵, Zancong Shen⁶, Shunqi Yan⁷, Li-Tain Yeh⁸ and Robert Keenan⁹, ¹Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan, ²Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Roseville, CA, ⁶Arthrosi Therapeutics, San Diego, CA, ⁷Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁸Arthrosi Therapeutics, Inc., Irvine, CA, ⁹Arthrosi Therapeutics, Chapel Hill, NC
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…
Abstract Number: 1810 • ACR Convergence 2023
Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Jiwon Hwang¹, Sungjun Hong², Kyunga Kim³, Jinhee Hur⁴, Yoosoo Chang⁵, Joong Kyong Ahn⁶ and Mira Kang⁷, ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea, ³Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University; Biomedical Statistics Center, Data Science Research Institute, Research Institute for Future Medicine, Samsung Medical Center; Department of Data Convergence & Future Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Food Science and Biotechnology, Sungkyunkwan University; Food Clinical Research Center, Institute of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, South Korea, ⁵Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine; Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁷Department of Digital Health, Samsung Advanced Institute of Health Sciences and Technology (SAIHST), Sungkyunkwan University; Health Promotion Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Digital Transformation Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Alcohol intake has been known to be interrelated with hyperuricemia and gout. However, the results of its influence are conflicting on serum uric acid…
Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Claudia Maria Gomez¹, Patricio Cardoso Peñafiel¹, Jose Antonio Angel-Sesmero¹, Marta Novella-Navarro² and Enrique Calvo-Aranda¹, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
Abstract Number: 1811 • ACR Convergence 2023
Strong Relationships Between Body Component Changes and Serum Uric Acid Variability
Jiwon Hwang¹, Mi Yeon Lee², Yeonghee Eun³ and Joong Kyong Ahn³, ¹Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, South Korea, ²Division of Biostatistics, Department of R&D Management, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Obesity has a well-known relationship with higher serum uric acid (SUA) levels. Skeletal muscles are another site for producing uric acid as the endogenous…
Abstract Number: 1796 • ACR Convergence 2022
Peripheral Vascular Disease and Sequelae in Individuals with Gout, Diabetes, or Both Among US Veterans
Nicole Leung¹, Michael Toprover¹, Charles Fang², Michael Pillinger³ and Jay Pendse⁴, ¹Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ²Department of Surgery Division of Vascular and Endovascular Surgery, University of Massachusetts Medical School, Worcester, MA, ³NYU Grossman School of Medicine, New York, NY, ⁴Division of Endocrinology, New York University Grossman School of Medicine and Endocrinology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY
Background/Purpose: Peripheral vascular disease (PVD) causes substantial morbidity and mortality. Patients with gout are known to have increased coronary artery disease risk but less is…
Abstract Number: 1797 • ACR Convergence 2022
Factors Driving Opioid Use in United States Veterans with Gout
Lindsay Helget¹, Bryant England¹, Punyasha Roul², Harlan Sayles¹, Alison Petro¹, Tuhina Neogi³, James O'Dell¹ and Ted Mikuls⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³Boston University School of Medicine, Boston, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with gout often seek care for painful flares and nearly one-third are prescribed opioids during acute ambulatory visits. Unfortunately, opioids do not address…
Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…
Abstract Number: 1799 • ACR Convergence 2022
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Naomi Schlesinger¹, Michael Pillinger² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²NYU Grossman School of Medicine, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: The American College of Rheumatology (ACR) developed an updated guideline in 2020 for the management of gout.1 This study evaluates US rheumatologists' stated adherence…
Abstract Number: 0001 • ACR Convergence 2022
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
John Botson¹, kenneth saag², Jeff Peterson³, Katie Obermeyer⁴, Brian LaMoreaux⁴, Suneet Grewal⁵, Amar Majjhoo⁶, John Tesser⁷ and Michael Weinblatt⁸, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²University of Alabama at Birmingham, Birmingham, AL, ³Western Washington Arthritis Clinic, Seattle, WA, ⁴Horizon Therapeutics plc, Deerfield, IL, ⁵East Bay Rheumatology Medical Group, Inc., San Leandro, CA, ⁶Shores Rheumatology, PC, Troy, MI, ⁷Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
Abstract Number: 1802 • ACR Convergence 2022
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Min Jung Kim¹, Mi Hyeon Kim², SE RIM CHOI², Youjin Jung², Ji In Jung², Ju Yeon Kim², Jee Won Chai³ and Kichul Shin⁴, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: To investigate whether monosodium urate (MSU) deposition measured by dual-energy computed tomography (DECT) could help predict acute flares after discontinuing colchicine prophylaxis in patients…
Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…
Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielmann², Corine Gaillez³, Weibin Bao⁴, Hugh O’Neill⁵, jacques-eric gottenberg⁶, Pierre-Marie Duret² and Laurent Messer⁷, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Colmar Civilian Hospitals, Colmar, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Colmar Civil Hospitals, Colmar, France
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].